1. Introduction {#s0005}
===============

The pyrimidine system is a very important pharmacophor core of naturally occurring and synthetic bioactive compounds, interacting with the synthesis and function of nucleic acids, interfering with biosynthetic pathways and competing for the same binding sites of naturally occurring pyrimidines ([@bb0120]). Modified pyrimidines are currently used as drugs; for example fluorouracil has cytostatic effects and is currently used in cancer therapeutics, azidothymidine (AZT) was the first applied drug for HIV treatment and bacimethrin (4-amino-5-hydroxymethyl-2-methoxypyrimidine) is known as the simplest pyrimidine antibiotics ([@bb0185]).

The K562 cell line ([@bb0145]) has been proposed as a very useful experimental system to identify antitumor compounds ([@bb0130; @bb0140; @bb0125]) acting by inducing terminal erythroid differentiation of this as well as other tumor cell lines ([@bb0035; @bb0030; @bb0025; @bb0045; @bb0080; @bb0160; @bb0165]). K562 cells exhibit a low proportion of hemoglobin-synthesizing cells under standard cell growth conditions, but are able to undergo terminal erythroid differentiation when treated with a variety of compounds, including short fatty acids ([@bb0080]), 5-azacytidine ([@bb0080]), mithramycin and chromomycin ([@bb0035; @bb0060]), cisplatin and cisplatin analogs ([@bb0030]), tallimustine ([@bb0025; @bb0080]), rapamycin ([@bb0065]), everolimus ([@bb0210]), psoralens ([@bb0130; @bb0140]) and resveratrol ([@bb0040]). Following erythroid induction, increase of expression of ε and γ globin genes is observed, leading to accumulation of Hb Portland (ζ~2~γ~2~) and Hb Gower 1 (ζ~2~ε~2~) ([@bb0080]).

The design and production of antiproliferative molecules targeting the K562 cell system might be of great interest for the development of cocktails exhibiting applications in the treatment of chronic myelogenous leukemia. For instance smenospongine ([@bb0015; @bb0020]), crambescidin 800 ([@bb0015; @bb0020]) and doxorubicin derivatives ([@bb0200]) were reported as molecules of possible interest for inhibiting of chronic myelogenous leukemia cell growth, stimulating terminal differentiation along the erythroid program. Some molecules, such as Pivanex (an HDAC inhibitor) ([@bb0180]) and a morpholine derivative of doxorubicin ([@bb0110]), are synergistic with the most common anti-chronic myelogenous leukemia agents, STI571 (Imatinib). In addition to synergistic effects, molecules inducing differentiation might be of great interest for treatment of Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines, as recently demonstrated for the phytoalexin resveratrol ([@bb0175]).

Recently we reported a novel class of C-5 linked N-1 alkylated uracil dimers rationally designed to potentially interact with adenine in biological systems. These pyrimidine derivatives have shown antiproliferative and erythroid differentiation activities toward human chronic myelogenous leukemia K562 cells ([@bb0005]). In this paper we report a screening study on a set of different modified C(5) uracil derivatives ([Table 1](#t0005){ref-type="table"}) for the evaluation of their antiproliferative effect in connection with erythroid differentiation pathways, and for defining a new class of drugs candidates for the treatment of chronic myelogenous leukemia.

2. Materials and methods {#s0010}
========================

2.1. Chemical synthesis of uracil compounds {#s0015}
-------------------------------------------

Compounds **1**, **2** and **4** were purchased from Sigma-Aldrich and tested without further purification. Synthesis of compounds **5**, **8**, **9**, **10** and **11** was previously reported in [@bb0005]. All syntheses started from uracil, thymine or 5-carboxyuracil (isoorotic acid) as described schematically in the [Results](#s0040){ref-type="sec"} section. Full synthetic procedures and characterization of compounds **3**, **12**, **13**, **14**, **15**, **16**, **17** and **18** are reported elsewhere (Accetta et al., 2010).

2.2. Cell culture conditions, proliferation assay and cell differentiation {#s0020}
--------------------------------------------------------------------------

The human K562 cells ([@bb0145]), obtained from the American Type Culture Collection (Rockville, Md., USA), were maintained in a humidified atmosphere of 5% CO~2~ at 37 °C in suspension culture using RPMI 1640 medium (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Analitical de Mori, Milan, Italy), 50 units/ml penicillin and 50 mg/ml streptomycin ([@bb0030]). For the experiments, cell were seeded at an initial concentration of 3 × 10^4^ cells/ml and cultured in the presence of increasing concentrations of compounds. Non-treated cells were considered as control. Cell growth, according to cell number/ml, was usually determined after 3, 4 and 5 days of culture, using a cell counter (Coulter Electronics, Hialeah, FL, USA). These time points were selected because between days 3 and 5 untreated control K562 cells are on the log phase of cell growth ([@bb0030]). All experiments were repeated at least 3 times. In order to determine the effects on the erythroid differentiation, cells were seeded at an initial concentration of 3 × 10^4^ cells/ml and the proportion of benzidine-positive cells was determined after 4--7 days of cell culture using a solution containing 0.2% benzidine in 0.5 M glacial acetic acid (10% H~2~O~2~) as previously described ([@bb0025; @bb0045]). Benzidine positivity indicates the presence of intracellular hemoglobin.

2.3. Transfection of K562 cells with fluorescence protein genes under the γ-globin and the β-globin gene promoters {#s0025}
------------------------------------------------------------------------------------------------------------------

K562 cells were stably transfected with the pCCL.Promβ.HcRed1.Promγ.EGFP, containing the green and red fluorescence protein (FP) genes under the control of the γ-globin and β-globin gene promoters, respectively ([@bb0090; @bb0135]). In this system, increases in the green and red signals are consistent with γ-globin and β-globin gene promoter driven activity, respectively. To determine the activity of chemical compounds in inducing the expression of γ-globin and β-globin genes, cells were seeded at 8000 cells/ml and treated with the appropriate concentration of the chemical inducer. After 5 days of culture, cells were assayed for fluorescent proteins expression. First of all they were analyzed under a fluorescence inverted microscope, using filters suitable for both green and red FPs. The fluorescence intensity was then determined by fluorescence-activated cell sorting (FACS) analysis.

2.4. FACS analysis {#s0030}
------------------

For the determination of fluorescence intensity by FACScan (Becton Dickinson, Franklin Lakes, NJ, USA), cells were harvested and washed. Then 1 × 10^4^ cells were analyzed by the CellQuest™ version 3.3 software (Becton Dickinson, Franklin Lakes, NJ, USA), using the fl1 channel to detect green fluorescence and fl3 channel to detect red fluorescence. The results were expressed as median fold, i.e. the ratio between the median fluorescence intensity values obtained in the presence and absence of treatment, respectively. A graphic presentation of data was finally obtained by histograms, showing the number of cells *versus* the expressed fluorescence intensity ([@bb0190]).

2.5. mRNA measurements {#s0035}
----------------------

RNA was isolated from K562 cells and measured by reverse transcription quantitative real-time polymerase chain reaction (qRT-PCR) as described ([@bb0045]) using gene-specific double fluorescence labeled probes in an ABI Prism 7700 Sequence Detection System version 1.7.3 (Applied Biosystems, Monza, Italy). The following primer and probe sequences were used: α-globin forward primer, 5′-CAC GCG CAC AAG CTT CG-3′; α-globin reverse primer, 5′-AGG GTC ACC AGC AGG CAG T-3′; α-globin probe, 5′-FAM-TGG ACC CGG TCA ACT TCA AGC TCC T-TAMRA-3′; γ-globin forward primer, 5′-TGG CAA GAA GGT GCT GAC TTC-3′; γ-globin reverse primer, 5′-TCA CTC AGC TGG GCA AAG G-3′; γ-globin probe, 5′-FAM-TGG GAG ATG CCA TAA AGC ACC TGG-TAMRA-3′; glycophorin A forward primer: 5′-CGG TAT TCG CCG ACT GAT AAA-3′; glycophorin A reverse primer: 5′-AAA GGC AGT CTG TGT CAG GT-3′; glycophorin A probe: 5′-FAM-AAA GCC CAT CTG ATG TAA AAC CTC TTC CCC T-TAMRA-3′; transferrin receptor forward primer: 5′-TCA GAGCGTCGGGATATCG-3′; transferrin receptor reverse primer: 5′-TGA ACT GCC ACA CAG AAG AAC A-3′, transferrin receptor probe: 5′-FAM-TGG CGG CTC GGG ACG GA-TAMRA-3′. The kit for quantitative qRT-PCR for ζ-globin mRNA and ε-globin mRNA was from Applied Biosystems (ζ-globin mRNA: Hs00923579_m1; ε-globin mRNA: Hs00362216_m1). The fluorescent reporter and the quencher were 6-carboxyfluorescein (FAM) and 6-carboxy-N,N,N′,N′-tetramethylrhodamine (TAMRA), respectively. For qRT-PCR, the reference gene was 18S; this probe was fluorescent-labeled with VIC (Applied Biosystems, Monza, Italy) ([@bb0035; @bb0045]).

3. Results {#s0040}
==========

3.1. Synthetic scheme of the compounds tested {#s0045}
---------------------------------------------

The C-5 position of pyrimidine nucleosides can be easily modified with a variety of different residues. Substitution at this position is often used for introducing substituents on DNA oligomers with reporter groups. In a general project, aimed at molecular engineering of peptide nucleic acid (PNA) derivatives (A. [@bb0010]), we prepared a set of N(1) and/or N(3) alkyl-C(5) modified uracil derivatives. Since these compounds are structurally analogs of modified nucleosides, they could be considered as potential drugs *per se*.

The list of compounds tested is reported in [Table 1](#t0005){ref-type="table"}. This set of compounds was chosen for screening since: i) it contains compounds alkylated at N1 and N3 positions or both; ii) it contains a series of C5 derivatives with different functional groups; iii) it has lipophilic groups in both the N1, N3, or C5 region of uracil; iv) it contains derivatives with intact uracil (and thymine) hydrogen bond pattern or lacking of the N3 hydrogen.

The synthetic pathways used for different compounds are reported in [Figs. 1 and 2](#f0005 f0010){ref-type="fig"} ([@bb0005]; Accetta et al., 2010).

Briefly, modification of uracil at both N1 and C5 positions was obtained in several ways. For the more reactive uracil and isoorotic acid, and in the presence of small electrophiles such as methyl iodide, the regioselective alkylation at N1 can be obtained by temporary protection of the N3 with trimethylsilyl ([@bb0005]) or benzoyl ([@bb0070]) groups. The latter method was used in the synthesis of **7** from **6**. Azidomethyl derivative **3** was obtained by reaction of uracil with formaldehyde, thus introducing a 5-hydroxymethyl derivative which could be further elaborated to azide by nucleophilic substitution (via a chloromethyl intermediate). Alkylation of **3** with α-bromoacetic acid derivatives led to compounds **15** and **16**. The latter was converted to **17**, bearing an amino group through Staudinger reduction. The amide derivative **18** was then obtained by reaction of the amino compounds with 2-naphthalenecarboxylic acid after activation of the latter with HBTU. Regioselective alkylation at N1 was obtained also by exploiting the higher reactivity of the N1 position in thymine and iodouracil toward sterically hindered electrophiles ([Fig. 2](#f0010){ref-type="fig"}), which allowed direct synthesis of compounds **9** (according to [@bb0055]) and **13**. The N1, N3-doubly alkylated compound **12** was obtained as a side product of thymine alkylation. Oxidation of thymine methyl group led to the N1-alkylated-5-carboxylic derivative **10** ([@bb0005]), which was then converted into the carboxyamide derivative **11** via HBTU activation and reaction with benzylamine. Hydrolysis of **13** with TFA provided derivative **14**, bearing a polar substituent in the N1-position.

3.2. Antiproliferative and erythroid differentiating activities of the uracil monomers {#s0050}
--------------------------------------------------------------------------------------

We first determined for all the synthesized molecules the effects on cell proliferation. To this aim, K562 cells were cultured in the presence of increasing concentrations of compounds and cell number/ml was determined after 3, 4 and 5 days of treatment. The results are shown in [Table 2](#t0010){ref-type="table"}, where it appears evident that the most active compounds with respect to antiproliferative effects (IC~50~ values lower that 150 μM) are compounds **3**, **9**, **11**, **12** and **18**, compound **9** being the most active molecule. However, among these molecules, only compound **9** is a very effective inducer of erythroid differentiation of K562 cells ([Table 2](#t0010){ref-type="table"}). When analysis of the proportion of benzidine-positive cell is performed, K562 cells cultured in the presence of 50 μM compound **9** display over 90% hemoglobin-expressing (benzidine-positive) cells. As far as the other compounds, only **8** and **18** are able to induce differentiation, but at very high concentrations (400 μM and 200 μM, respectively). When the same compounds were added at higher concentrations, no further increase in the proportion of benzidine-positive cells was obtained (data not shown). According with these results, compound **9** was analyzed in more detail.

3.3. Effects of compound **9** on proliferation and erythroid differentiation of K562 cells {#s0055}
-------------------------------------------------------------------------------------------

The analysis of the effects of compound **9** on the K562 cellular system is shown in [Fig. 3](#f0015){ref-type="fig"}. In the experiment shown in [Fig. 3](#f0015){ref-type="fig"}A, K562 cells were cultured for 6--7 days in the absence or in the presence of increasing concentrations (10, 30, 50 μM) of compound **9**. As it is clearly evident, a concentration-dependent inhibition of cell growth was observed. [Fig. 3](#f0015){ref-type="fig"}C reports the effect on the proliferation of K562 cells after 3 days of treatment with compound **9** at different concentrations. IC~50~ was obtained at about 30 μM. [Fig. 3](#f0015){ref-type="fig"}B shows the percentages of differentiation induced by compound **9** at different concentrations (10, 30, 50 μM). We like to underline that more than 60% benzidine positive cells are detectable after only 3 days of induction, demonstrating that the inducing effects of compound **9** was very high, and it can be considered among the most powerful inducer of K562 differentiation (see also [Table 3](#t0015){ref-type="table"}). Despite the fact that there is no linear relationship between proportion of differentiated cells and cells with lower proliferation efficiency, the data summarized in [Fig. 3](#f0015){ref-type="fig"}C and D demonstrate that 30 μM compound **9** is a concentration sufficient to (a) inhibit cell growth and (b) induce differentiation of the majority of treated K562 cells. Further experiments are required to verify whether decrease of cell growth is a pre-requisite for differentiation or is the cause of this feature. Supplementary Fig. 1 shows a microscopic analysis of K562 cells cultured taken after 6 days of K562 cell cultured in the absence or in the presence of 30 μM compound **9**. In these assays, the blue-color of benzidine-stained cells is compatible with high accumulation of hemoglobin ([@bb0025]).

In a second set of experiments, the biological activity of compound **9** was compared to that of 5-fluorouracil (5-FU), extensively employed as anti-tumor agent in leukemias ([@bb0155; @bb0195]). Interestingly, as far as the effects on cell proliferation, similar IC~50~ values were obtained when compound **9** and 5-FU were employed. On the other hand the effects of compound **9** and 5-FU on erythroid differentiation were found to be very different, being only compound **9** able to activate the full program of differentiation. As expected, uracil, in agreement with the first set of results depicted in [Table 2](#t0010){ref-type="table"}, did not show any effects on K562 with respect to inhibition of cell proliferation and induction of erythroid differentiation ([Table 3](#t0015){ref-type="table"}).

3.4. Effects of compound **9** on the transcriptional activity of the γ-globin and the β-globin gene promoters of K562 cells {#s0060}
----------------------------------------------------------------------------------------------------------------------------

To determine the effects of compound **9** on the transcription of the globin genes, we used a clonal K562 cell population stably transfected with a reporter construct, carrying the genes for the green (EGFP) and red (RFP) fluorescent proteins (FP), under the control of the γ-globin and the β-globin promoters, respectively ([@bb0090; @bb0135]). To compare the relative effect of compound **9**, the experiment depicted in [Fig. 4](#f0020){ref-type="fig"} was performed. Cells were treated with 30 μM compound **9**, isolated after 5 days and employed in FACS analysis; this assay demonstrated that compound **9** enhanced EGFP by 2.10 ± 0.63 fold, and the increase in RFP was 1.39 ± 0.10 fold, indicating an effect of compound **9** on the transcription directed by both the γ-globin and β-globin gene promoters. On the contrary, as recently published by our research group, other erythroid differentiation inducers have a stimulatory selectivity only for the γ-globin gene promoter ([@bb0090] and data not shown).

3.5. Effects of compound **9** on biochemical parameters associated to the activation of the K562 erythroid phenotype {#s0065}
---------------------------------------------------------------------------------------------------------------------

As we can see in [Fig. 5](#f0025){ref-type="fig"}, exposure for 6 days of K562 cells to 30 μM compound **9** stimulates a sharp accumulation of α-globin mRNA (black symbols) and γ-globin mRNA (gray symbols). The effects of compound **9** on the transcription of α-globin mRNA and γ-globin mRNA were analyzed by qRT-PCR amplifications and found to be clearly associated with the ability of compound **9** to induce erythroid differentiation of K562 cells. Compounds **10** and **11**, which induce erythroid differentiation to a much lower extent ([Table 3](#t0015){ref-type="table"}), induce only slight increase of accumulation of α-globin ([Fig. 5](#f0025){ref-type="fig"}B) and γ-globin ([Fig. 5](#f0025){ref-type="fig"}C) mRNAs. The qRT-PCR data concerning the effects of compound **9** are fully in agreement with HPLC analyses, showing that this molecule induces a sharp increase of embryonic and fetal hemoglobins (Supplementary Fig. 2).

Further qRT-PCR data demonstrated that also the embryonic-type ζ- and ε-globin mRNAs are induced by compound **9** ([Fig. 6](#f0030){ref-type="fig"}). In addition, the effects of compound **9** on other genes involved in the expression of erythroid program. To this aim the mRNA coding glycophorin A ([@bb0105; @bb0095; @bb0205]) and transferrin receptor ([@bb0075; @bb0100]) were studied by qRT-PCR. The results obtained are shown in [Fig. 6](#f0030){ref-type="fig"} and demonstrate that both relative amounts of glycophorin A and transferrin receptor mRNAs increase following treatment with compound **9**, confirms the induction of erythroid pathway by this compound.

3.6. The induction of erythroid differentiation of compound **9** is not associated with the activation of the apoptotic pathway {#s0070}
--------------------------------------------------------------------------------------------------------------------------------

Since several inducers of erythroid differentiation are also strong inducers of apoptosis of K562 cells (for instance mithramycin and psoralens) ([@bb0025; @bb0130; @bb0140]) the experiments described in Supplementary [Figs. 3, 4 and 5](#f0015 f0020 f0025){ref-type="fig"} were performed. Flow cytometry analysis (Supplementary Fig. 3) demonstrates no major alteration of cell cycle parameters and no accumulation of sub-G1 cells (a hallmark of apoptosis). Apoptosis was not evident also when Annexin V--FITC staining was performed (Supplementary Fig. 4) and using the DeadEnd TUNEL assay (Supplementary Fig. 5).

4. Discussion {#s0075}
=============

The biological activity of the derivatives tested in this study can lead to the following alternative effects: (a) a strong antiproliferative effect linked to a high level of erythroid differentiation activity and (b) an antiproliferative effect independent from the activation of the erythroid program ([Table 2](#t0010){ref-type="table"}). The highest antiproliferative effect and erythroid induction ability were exhibited by compound **9**, a thymine derivative bearing a *n*-octyl chain on nitrogen N(1), whereas thymine (compound **2**) did not show any effect, suggesting the importance of the linear alkyl chain in position N(1). The insertion of the alkyl chain in both N(1) and N(3) positions of thymine (compound **12**) brought a loss of erythroid induction activity with retention of antiproliferative effect, suggesting the fundamental role of hydrogen in position N(3) of thymine for the erythroid induction activity. Appreciably, even if in some cases much lower, erythroid differentiation activity was shown by derivatives **8**, **10** and **18**. Activity of compound **10** can be rationalized considering its structural similarities to compound **9** (methyl group substituted by COOH); compounds **8** and **18** show the same pattern, when properly oriented ([Fig. 7](#f0035){ref-type="fig"}); therefore, they can be considered as "C-nucleoside" equivalent ([@bb0150]) of compound **9** with exchange of the role of N(1) and C(5), which leads to N(3)-H in the same relative orientation with respect to the lipophilic group as in thymine derivatives.

In conclusion we found a simple thymine derivative, N(1)-octyl-thymine that exhibit strong antiproliferative activity, high ability to induce terminal erythroid differentiation without activation of the apoptotic pathway. To our knowledge this compound should be considered among the most efficient inducers of erythroid differentiation of K562 cells.

However, this work should be considered as the starting point for the development of more effective and specific drugs for the induction of terminal erythroid differentiation, with the aim of leading new insights in the treatment of neoplastic diseases with molecules acting by inducing differentiation rather than simply by exerting cytotoxic and/or antiproliferative effects. Compound **9** might be of some interest since it strongly inhibits cell growth (the activity is similar to that displayed by 5-fluorouracil), but at the same time does induce erythroid differentiation. In this respect, the development of new compounds against chronic myelogenous leukemia cell lines might be of great interest, since it has been already demonstrated that synergistic effects of molecules inducing differentiation can be useful for the efficient treatment of chronic myelogenous leukemia ([@bb0110; @bb0180]).

In addition, and more importantly, Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines can be treated with erythroid inducers, as recently demonstrated using the phytoalexin resveratrol ([@bb0175]). It should be interesting to determine the activity of compound **9** in Imatinib-resistant cell lines, since the effects of resveratrol as erythroid-inducing agent are significantly different from those displayed by compound **9** in respect to induction of globin mRNAs ([@bb0040]) and activation of apoptosis and cell-cycle alterations ([@bb0175]).

On the other hand, molecules similar to compound **9** might be of interest for the experimental treatment of β-thalassemic erythroid cells, for which the induction of γ-globin mRNA could be very beneficial ([@bb0060; @bb0080]).

In this respect it has been demonstrated that inducers of K562 erythroid differentiation are often able to induce fetal hemoglobin production in erythroid cells isolated from β-thalassemia patients ([@bb0080]).

Appendix A. Supplementary data {#s0080}
==============================
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![Synthetic pathways used for derivatives obtained from uracil. i) CH~2~O, Et~3~N, 60 °C, overnight; ii) HCl, 37 °C, 4 h, r.t.; iii) NaN~3~, DMF, r.t., 2 h; iv) BrCH~2~COOR; K~2~CO~3~, 0 °C to r.t., overnight; v) PPh~3~, THF, rt, overnight, then TFA; vi) a) BzCl acetonitrile/pyridine, r.t. 24 then b) K~2~CO~3~ , water/dioxane, r.t., 40 min; and c) NaHCO~3~ sat r.t. 1 h; vii) CH~3~I, DMF, r.t., 3 h.](gr1){#f0005}

![Synthetic pathways used for derivatives obtained from thymine and 5-iodouracil. i) For **9** Br-n-C~8~H~17~ , NaH as base, DMF, 80 °C, 4 h; for **13** BrCH~2~COOtBu and K~2~CO~3~ as base, DMF; ii) 2,6-lutidine, K~2~S~2~O~8~, CuSO~4~, H~2~O/AcCN, 80 °C, 1,5 h; iii) NaClO~2~, NaH~2~PO~4~; *t*-BuOH/THF, room temp, 24 h).; iv) TFA, DCM, 0 °C, 1h.](gr2){#f0010}

![Effects of compound **9** on the proliferation (A) and erythroid differentiation of K562 cells (B). Cells were cultured for 6--7 days in the absence (![](fx1.gif)) or in the presence of increasing concentrations 10 μM (![](fx2.gif)), 30 μM (![](fx3.gif)), and 50 μM (![](fx4.gif)) of compound **9**. The effect on the proliferation of K562 after 3 days of treatment with compound **9** at different concentrations (C) and the percentage of benzidine-positive cells after 6 days of treatment (D). The values in treated cultures represented in C) were compared with untreated control cultures (taken as 100%). The data represents the mean ± S.D. of three independent experiments.](gr3){#f0015}

![Representative example of FACS analysis of a K562 cell clone containing the reporter construct pCCL.Promβ.HcRed1.Promγ.EGFP, untreated or treated with compound **9** 30 μM for 5 days. (A,B) Histogram plots obtained from untreated (solid lines) or treated (dotted lines) cells, showing the relationship between number of cells and intensity of expressed fluorescence, green (A) or red (B), respectively. (C) Dot plots obtained from untreated (−, upper panel) or treated (+, lower panel) cells, showing the cell population distribution as a function of the two different fluorescences.](gr4){#f0020}

![Accumulation of α-globin mRNA (A, black columns) and γ-globin mRNA (A, gray columns) in K562 cells treated for 6 days with 30 μM compound **9**. qRT-PCR amplifications were performed on RNA from untreated or treated cells using primers amplifying 18S ribosomal RNA as reference gene. Results are presented as fold increase of α-globin and γ-globin mRNAs with respect to untreated cells. (B,C) Effect of compounds **9**, **11** and **10** on accumulation of α-globin mRNA (B) and γ-globin mRNA (C). The results of untreated cells were taken as 1. Results represent the average ± S.D. of three independent experiments.](gr5){#f0025}

![Accumulation (fold increase in respect to control uninduced cells) of the α-like ζ- and α-globin mRNAs, the β-like ε- and γ-globin mRNA, the glycophorin A and transferrin receptor mRNAs in K562 cells treated for 6 days with 30 μM compound **9**. Results represent the average ± S.D. of three independent experiments.](gr6){#f0030}

![Structural similarities of the compounds most effective as erythroid inducers; compounds **18** and **8** are oriented as C-nucleoside analogs.](gr7){#f0035}

###### 

Schematic description of compounds screened in the present study.

                 Compound          R1                        R2               R3
  -------------- ----------------- ------------------------- ---------------- -----
  ![](fx5.gif)   **1**             --H                       --H              --H
  **2**          --H               --CH~3~                   --H              
  **3**          --H               --CH~2~N~3~               --H              
  **4**          --CH~2~COOH       CH~3~                     --H              
  **5**          --H               --COOCH~3~                --H              
  **6**          --H               --H                       --COPh           
  **7**          --CH~3~           --H                       --COPh           
  **8**          --CH~3~           --CONH*n*C~4~H~9~         --H              
  **9**          --*n*C~8~H~17~    --CH~3~                   --H              
  **10**         --*n*C~8~H~17~    --COOH                    --H              
  **11**         --*n*C~8~H~17~    --CONHCH~2~Ph             --H              
  **12**         --*n*C~8~H~17~    --CH~3~                   --*n*C~8~H~17~   
  **13**         --CH~2~COO*t*Bu   --I                       --H              
  **14**         --CH~2~COOH       --I                       --H              
  **15**         --CH~2~COO*t*Bu   --CH~2~N~3~               --H              
  **16**         --CH~2~COOEt      --CH~2~N~3~               --H              
  **17**         --CH~2~COOEt      --CH~2~NH~2~              --H              
  **18**         --CH~2~COOEt      --CH~2~NHCO(2-naphthyl)   --H              

Name (alternative name): **1**, uracil; **2**, thymine (5-methyluracil); **3**, 5-azidomethyluracil; **4**, (thymin-1-yl)acetic acid (1-(carboxymethyl)thymine); **5**, methyl 5-uracilcarboxylate (methyl isoorotate); **6**, 3-benzoyluracil; **7**, 3-benzoyl-1-methyluracil; **8***N*-butyl-1-methyl-5-uracilcarboxamide; **9**, 1-octylthymine; **10**, 1-octyl-5-uracilcarboxylic acid (1-octylisoorotic acid); **11**, *N*-benzyl-1-octyl-5-uracilcarboxamide; **12**, 1,3-dioctylthymine; **13**, *t*-butyl (5-iodouracil-1-yl)acetate; **14**, (5-iodouracil-1-yl)acetic acid; **15**, *t*-butyl (5-azidomethyluracil-1-yl)acetate; **16**, ethyl (5-azidomehtyluracil-1-yl)acetate; **17**, ethyl (5-aminomethyluracil-1-yl)acetate; **18**, ethyl \[5-(*N*-(2-naphthylcarboxyl)aminomethyl)uracil-1-yl\]acetate.

###### 

Antiproliferative activity (IC~50~)[a](#tf0005){ref-type="table-fn"} and induction of erythroid differentiation[b](#tf0010){ref-type="table-fn"} (% B+ cells) of uracil derived-compounds on erythroleukemia K562 cells line.

  Compound   IC~50~            \% B+ cells   Concentration
  ---------- ----------------- ------------- ---------------
  **1**      \> 400 μM         1.1 ± 0.8     400
  **2**      \> 400 μM         1.3 ± 0.6     400
  **3**      120.05 ± 4.7 μM   4.1 ± 1.2     100
  **4**      \> 400 μM         2.0 ± 0.9     400
  **5**      \> 800 μM         7.3 ± 1.9     800
  **6**      350.7 ± 15.9 μM   1.1 ± 0.5     400
  **7**      650.6 ± 12.4 μM   1.5 ± 0.8     800
  **8**      488 ± 68 μM       12 ± 1.9      400
  **9**      29.4 ± 1.2 μM     98 ± 3.6      50
  **10**     268 ± 15.5 μM     25 ± 2.9      200
  **11**     66.54 ± 13 μM     2.2 ± 1.0     100
  **12**     29.7 ± 1.4 μM     2.1 ± 0.9     50
  **13**     \> 400 μM         1.2 ± 0.2     400
  **14**     \> 400 μM         1.6 ± 0.8     400
  **15**     721.3 ± 20.9 μM   2.3 ± 0.6     800
  **16**     764.2 ± 25.6 μM   2.1 ± 0.8     800
  **17**     \> 800 μM         2.0 ± 0.9     800
  **18**     115 ± 16 μM       30 ± 4.9      200

Results are presented as average ± S.D. (three independent experiments performed).

Values are expressed as average ± S.D. (three independent experiments performed) after 6 days of treatment at concentrations close to those needed to obtain 50% inhibition of cell growth after 3 day culture period (and reported of the far right column).

###### 

Antiproliferative effects (IC~50~)[a](#tf0015){ref-type="table-fn"} and induction of erythroid differentiation[b](#tf0020){ref-type="table-fn"} (% B+ cells) of uracil, compound **9** and 5-fluorouracil on K562 cell line.

  Compound         IC~50~            \% B+ cells
  ---------------- ----------------- -------------
  Uracil           \> 500 μM         1.2 ± 0.2
  Compound 9       17.52 ± 2.88 μM   92.3 ± 2.1
  5-Fluorouracil   17.73 ± 2.23 μM   3.1 ± 0.6

Results are presented as average ± S.D. (three independent experiments performed) of concentration needed to obtain 50% inhibition of cell growth after 3 days culture period.

Values are expressed as average ± S.D. (three independent experiments performed) after 6 days of treatment.
